Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Gastric Bypass Status
Interventions: rivaroxaban; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Multiple Sclerosis, Gait Disorders, Neurologic, Cognitive Impairment
Interventions: Dual-task gait, Single-task gait; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Pain, Postoperative, Amputation
Interventions: Liposomal bupivacaine, Bupivacaine Hydrochloride 0.5 % Injectable Solution; Drug
Lead sponsor: Aurora Quaye; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Conditions: HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions: Radiation Therapy, Pertuzumab, Trastuzumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Evanston, Illinois

Conditions: Melanoma
Interventions: Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Diabetes BOOST, Usual Care; Behavioral
Lead sponsor: Daniel Amante; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Worcester, Massachusetts

Conditions: Colorectal Cancer (Diagnosis), Anal Cancer, Sexual Dysfunction Female
Interventions: Mind-Body Group Intervention, Enhanced Usual Care Control (EUCC); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urinary Tract Infections
Interventions: Perineal Wipe; Other
Lead sponsor: Joanna A. Orzel; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
Interventions: Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna, Melphalan, Filgrastim, CliniMACS System; Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions: Fludarabine, Cyclophosphamide, Transplantation; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 4 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\), Hidradenitis Suppurativa, Acne Inversa
Interventions: Normal saline, Botulinum toxin type A; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Guilford, Connecticut

Conditions: Bone Metastases
Interventions: Lazanda; Drug
Lead sponsor: Joseph Ma; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Anorexia Nervosa
Interventions: rTMS treatment using BrainsWay Model 104 system with H1-Coil, sham TMS using BrainsWay Model 104 system with H1-Coil; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Lung Cancer
Interventions: Questionnaire, Patient Interview, Audio recordings of clinical consultations, 2-hour empathic communication skills training, Standardized Patient Assessments, Training evaluation, Patient recruitment; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Knee Osteoarthritis
Interventions: Mind-body exercise and education; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 130
States / cities: Tucson, Arizona • Burbank, California • La Jolla, California + 92 more

Conditions: Covid19
Interventions: Antiviral Agents, Monoclonal antibody; Drug
Lead sponsor: Pregistry; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions: Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Impulsive Behavior
Interventions: anodal tDCS over the rIFG,, anodal tDCS over the lOFC,, sham tDCS stimulation condition; Device
Lead sponsor: Lifespan; Other
Eligibility: 13 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Riverside, Rhode Island

Conditions: Perioperative Pain, Perioperative Anxiety
Interventions: Virtual Reality Distraction; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anxiety, Osteoarthritis
Interventions: Music via Headphones; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Use
Interventions: A19010-W, B19010-F; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 6
States / cities: Rogers, Arkansas • Lexington, Kentucky • Springfield, Missouri + 3 more

Conditions: Intraocular Inflammation, Suspected Endophthalmitis
Interventions: Non Applicable; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 155,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Search by objective public record fields.

Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery

Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis

Liposomal Bupivacaine vs Continuous Nerve Catheters for Below the Knee Amputations

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors

To Wipe or Not To Wipe?: That Is The Question

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

Botulinum Toxin-A for Hidradenitis Suppurativa

Lazanda in Cancer Patients Receiving Palliative Radiation

Transcranial Magnetic Stimulation (TMS) in the Treatment of Anorexia Nervosa

Clinician-Patient Communication in Lung Cancer Care

Mind-body Therapy (Remotely Delivered) for Knee Osteoarthritis

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

COVID-19 International Drug Pregnancy Registry

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Modulating Impulsivity in Suicidal Adolescents With Transcranial Direct Current Stimulation (tDCS)

The Use of Virtual Reality to Reduce Anxiety and Pain in Perioperative Settings

Preoperative Music Intervention for Anxiety in Hip and Knee Arthroplasty

CSD190103: A Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022